Company to Report Fourth Quarter and Full Year 2004 Financial Results on February 17, 2005
SAN DIEGO, Jan 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today its participation in the American Academy of Orthopaedic Surgeons (AAOS) 2005 Annual Meeting at the Washington Convention Center in Washington, D.C., February 23-27, 2005.
At the AAOS 2005 Annual Meeting, the Company will be showcasing its leading spine surgery products and technologies including the most recent additions to the Company's MAS(TM) platform: SpheRx(TM) Pedicle Screw System; MaXcess(TM) Micro-Access and; NeuroVision(R) Nerve Root Retractor, all launched during the third quarter of 2004. NuVasive products and technologies will be located at Booth 203.
Company executives present at the AAOS 2005 Annual Meeting will include Alexis V. Lukianov, Chairman and Chief Executive Officer, Keith Valentine, President, Kevin C. O'Boyle, Executive Vice President and Chief Financial Officer, Pat Miles, Senior Vice President of Marketing and Jim Skinner, Vice President of Sales.
Alexis V. Lukianov, Chairman and Chief Executive Officer, remarked, "We look forward to our participation in the largest and most important orthopaedic conference of the year. Investors, financial analysts and members of the media are encouraged to visit the NuVasive booth and interact with our senior management to learn more about the Company's leading spine surgery products and technologies and the benefits they offer to spine surgeons and patients."
Separately, the Company announced it will release financial results for the fourth quarter and full year ended December 31, 2004 on Thursday, February 17, 2005 after the market close with an accompanying conference call at 5:00 p.m. EST / 2:00 p.m. PST. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. The dial-in numbers are 1-800-811-0667 for domestic callers, and 1-913-981-4901 for international. The reservation number for both is 6244490. After the live Web cast, the call will remain available on NuVasive's Web site, http://www.nuvasive.com, through March 17, 2005. In addition, a telephonic replay of the call will be available until March 8, 2005. The replay dial-in numbers are 1-888-203-1112 for domestic callers and 1-719-457-0820 for international callers. Please use reservation code 6244490.
NuVasive is a medical device company focusing on the design, development and marketing of products for use in minimally disruptive surgical treatments for the spine. NuVasive's Maximum Access Surgery (MAS(TM)) product platform includes the NeuroVision(R) nerve avoidance system, MaXcess(TM) spine access system, and specialized implants. NuVasive also offers classic fusion implant products for use in spine surgery and has an R&D pipeline emphasizing motion preservation products such as total disc replacement (TDR).
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "planned," "expects," "believes," "strategy," "opportunity," "anticipates" and similar words. These statements may include, among others, plans, strategies and objectives of management for future operations; any statements regarding proposed new products, services or developments; any statements regarding future economic conditions or financial or operating performance; statements of belief and any statements of assumptions underlying any of the foregoing. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to, the rapidly changing and competitive nature of the medical device industry, NuVasive's ability to convince surgeons to use its products, the ability of patients to obtain third-party reimbursement for surgical procedures employing NuVasive's products, risks related to government regulation of medical devices, risks related to NuVasive's ability to effectively manage the growth of its business, risks related to ownership and enforcement of intellectual property rights, NuVasive's ability to successfully develop new products, and other risks and uncertainties more fully described in NuVasive's Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and NuVasive's Prospectus filed pursuant to Rule 424 under the Securities Act of 1933, as amended, with the Securities and Exchange Commission on May 13, 2004. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.
Kevin C. O'Boyle, Chief Financial Officer of NuVasive, Inc.,
+1-858-271-7070, firstname.lastname@example.org; or
Stephanie Carrington, +1-646-536-7017, email@example.com, or
Greg Tiberend, +1-646-536-7005, firstname.lastname@example.org,
both of The Ruth Group, for NuVasive, Inc.